Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

Koji Miyahara, Kazuhiro Nouso, Yuki Morimoto, Yasuto Takeuchi, Hiroaki Hagihara, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Shouta Iwadou, Yoshiyuki Kobayashi, Koichi Takaguchi, Yoshitaka Takuma, Hiroyuki Takabatake, Kohsaku Sakaguchi, Kazuhide Yamamoto, Shin ichi FujiokaToshiya Osawa, Kazuya Kariyama, Junichi Toshimori, Haruhiko Kobashi, Hirokazu Miyatake, Shuji Uematsu, Ryoichi Okamoto, Yasuyuki Araki, Masafumi Tatsukawa, Kazuhisa Yabushita, Toshinari Shimoe, Tatsuro Sakata, Toshihiko Kaneyoshi, Manabi Miyashita, Yasuhiro Makino, Akio Moriya, Masaharu Ando, Nobuyuki Baba, Tomonori Seno, Takuya Nagano, Eiji Matsumoto, Hiroki Takayama

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. Methods: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n=23) and stopped (n=13) sorafenib at first radiological PD. Results: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P=0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P=0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P=0.085). Conclusion: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.

Original languageEnglish
Pages (from-to)296-301
Number of pages6
JournalHepatology Research
Volume44
Issue number3
DOIs
Publication statusPublished - 2014

    Fingerprint

Keywords

  • Hepatocellular carcinoma
  • Sorafenib
  • Survival beyond first progression

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Miyahara, K., Nouso, K., Morimoto, Y., Takeuchi, Y., Hagihara, H., Kuwaki, K., Ohnishi, H., Ikeda, F., Miyake, Y., Nakamura, S., Shiraha, H., Takaki, A., Iwadou, S., Kobayashi, Y., Takaguchi, K., Takuma, Y., Takabatake, H., Sakaguchi, K., Yamamoto, K., ... Takayama, H. (2014). Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatology Research, 44(3), 296-301. https://doi.org/10.1111/hepr.12123